Can Semaglutide Damage Your Liver? What We Know Right Now

You're worried semaglutide might be harming your liver, here's the reassuring but nuanced picture

Most people asking this question have either read something alarming online or started noticing upper abdominal discomfort and jumped to a reasonable conclusion. The concern is understandable. You're taking a medicine that affects digestion, appetite and metabolism, the liver sits right in the middle of all three.

What the clinical trials actually show is the reverse of harm. Across the STEP programme, semaglutide was associated with meaningful reductions in liver fat content and improvements in ALT and AST levels, the blood markers doctors use to track liver stress. That body of evidence is what led the MHRA to grant conditional approval in early July 2026 for Wegovy to treat MASH, a progressive form of fatty liver disease involving scarring of liver tissue. You can read about that approval on GOV.UK's announcement of Wegovy's MASH authorisation. If you've been wondering whether semaglutide causes liver damage, the short answer from the trial data is that it doesn't, and for most adults the direction of the evidence is protective.

There is, however, a nuance worth understanding. People with severe liver impairment were not well represented in the major trials, so prescribers apply extra caution for that group. If your liver function is significantly reduced, your prescriber will weigh up whether semaglutide is suitable at all. For most people with mild-to-moderate liver involvement, the picture remains broadly positive, but individual assessment matters. Our overview of Wegovy covers the licensed indications and what the prescription process involves.

What does raise liver-related concerns while taking semaglutide, and what's probably something else

Semaglutide slows gastric emptying and can cause nausea, bloating and upper abdominal discomfort, especially in the first weeks of treatment. These sensations sit high in the abdomen and can feel vaguely liver-adjacent. They are almost always GI in origin, not hepatic. The NHS semaglutide medicines page explains which side effects are common and what to watch for.

The side effect that genuinely warrants attention is gallbladder disease. Rapid weight loss of any kind (diet, surgery or medicine) can increase the risk of gallstones, and semaglutide is no exception. The gallbladder sits just below the liver, so gallstone pain can feel like liver pain. Symptoms to take seriously include severe pain in the upper right abdomen or under the right shoulder blade, fever, or nausea accompanying the pain. Tell a doctor quickly if those arise.

True liver injury from semaglutide is not an established pattern in the clinical evidence. Reports exist in pharmacovigilance databases, as they do for almost any medicine, but causality is difficult to establish in people who often have pre-existing metabolic liver disease. If you want to understand more specifically whether Wegovy can damage the liver, our dedicated page looks at the evidence in detail, including what the pharmacovigilance data does and doesn't tell us. If you're experiencing yellowing of the skin or whites of the eyes, very dark urine, or extreme fatigue alongside abdominal pain, those do warrant a same-day call to your GP or, if severe, an urgent assessment. You can also report any suspected side effects through the MHRA's Yellow Card scheme.

Pregnancy, breastfeeding, and liver conditions that need specialist input first

Semaglutide is not recommended during pregnancy, breastfeeding, or while actively trying to conceive. If your liver condition is part of a broader picture that includes pregnancy-related liver disease, that conversation belongs with your obstetrician and hepatologist, not an online service. For more on semaglutide during pregnancy, our page on Wegovy and pregnancy sets out what the guidance says.

For people with autoimmune liver conditions, hepatitis B or C, or who are on medicines with significant hepatic metabolism, the question isn't whether semaglutide damages the liver in general, it's whether it's the right fit for your specific profile. That takes a prescriber who can see your full picture. Under-18s are not licensed for Wegovy.

If you have an existing liver condition and are curious whether weight-loss treatment might help (fatty liver in particular is a common reason people explore this) a conversation with a clinician is genuinely the right starting point. It's also worth knowing that if you're in the early stages of exploring treatment options, you can start a free consultation with our prescribers, who review every application themselves on the same day and can tell you plainly whether semaglutide is appropriate for your situation. There is no algorithm involved.

What's still uncertain, and how to use that uncertainty sensibly

Long-term real-world data on semaglutide and liver health beyond the clinical trial timeframes is still building. The trials ran for up to 68–72 weeks; we are now in the phase where post-marketing surveillance and registry studies are adding to that picture. The MASH indication approval is conditional precisely because the evidence, while promising, is still maturing.

What that means practically: if your prescriber monitors your liver enzymes periodically while you're on semaglutide, that is good clinical practice, not a sign something is expected to go wrong. Plenty of people get a blood test done at their GP surgery in the morning and have their results by the time they're back from the school run. Routine monitoring is straightforward. Our page looking at whether Wegovy damages your liver covers what to make of routine liver enzyme results and when they actually warrant further investigation.

Our clinical team's approach is set out on the clinical team page. If you have questions about a specific liver situation, the contact page gets you to our aftercare team seven days a week. For a broader read on how semaglutide interacts with the body, the page exploring how semaglutide can affect your liver goes into the mechanism in more detail.